SCULPTRA AND SCULPTRA AESTHETIC
Q-Med AB · Decision date Aug 3, 2004
What did the FDA approve?
The August 3, 2004 approval for SCULPTRA (P030050) covers the device as intended for restoration and/or correction of the signs of facial fat loss, termed lipoatrophy, in people with human immunodeficiency virus. The applicant is Q-Med AB, and the product code LMH places it in the implant, dermal, for aesthetic use category under the general and plastic surgery specialty.
The decision field records an APPR outcome, but the supplement type and supplement reason fields are absent. This means the record does not state whether the action is an original PMA approval or a supplement, and no manufacturing or labeling change is described. The statement reports an intended use; it does not provide independent evidence of safety or clinical effectiveness.
FDA approval order statement
APPROVAL FOR SCULPTRA. THE DEVICE IS INTENDED FOR RESTORATION AND/OR CORRECTION OF THE SIGNS OF FACIAL FAT LOSS (LIPOATROPHY) IN PEOPLE WITH HUMAN IMMUNODEFICIENCY VIRUS.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Aug 3, 2004
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P030050
- Regulatory pathway
- Premarket approval application
- Applicant
- Q-Med AB
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Aug 3, 2004
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P030050 received
Application receipt date recorded by FDA.
P030050 · FDA decision
APPR
P030050/S056 · Related supplement
SCULPTRA (injectable poly-L Lactic acid)
Timeline entries are records held by MedtechLedger for P030050. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030050
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SCULPTRA (injectable poly-L Lactic acid)P030050/S056 | Q-Med AB | PMA supplement | Sep 17, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Q-Med AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Seminariegatan 21, Uppsala, SE-752-28
Sources and methodology
- Original FDA record: P030050
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



